Trials / Terminated
TerminatedNCT00533351
Safety and Efficacy of AGN201781 in Neuropathic Pain
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN201781 | AGN201781 50 mg capsules three-times daily for 2 weeks |
| DRUG | placebo | placebo 50 mg capsules three-times daily for 2 weeks |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-09-21
- Last updated
- 2016-02-24
- Results posted
- 2012-01-19
Locations
2 sites across 2 countries: Australia, Germany
Source: ClinicalTrials.gov record NCT00533351. Inclusion in this directory is not an endorsement.